Skip to main content
. 2024 Feb 27;11:1208074. doi: 10.3389/fnut.2024.1208074

Table 2.

Case 1: summary of laboratory testing from 2014 to 2018.

Date of laboratory testing
6/23/14 8/4/16 10/20/16 1/6/17 6/19/17 10/19/17 3/8/18
DNA (DS) antibody, IU/ml a 3 (negative) 5 (indeterminate) 5 (indeterminate) 6 (indeterminate)
Sjögren’s antibody: SS-A >8 (positive) >8 (positive) >8 (positive)
Sjögren’s antibody: SS-B 3.3 (positive) <1 (negative) <1 (negative)
ANA b positive positive
Lupus Anticoagulant (LAC) c not detected
Cardiolipin antibody-IgM d 25 (high) 24 (high)
Cardiolipin antibody-IgG d <14 (negative) <14 (negative)
Cardiolipin antibody-IgA d <11 (negative)
PTT screen (LAC) e 43 (high) 37 (normal)
CRP (mg/dL) f 0.1 (in range)
C3 (mg/dL) g 96 (in range) 91.6 (in range)
C4 (mg/dL) g 38 (in range) 33 (in range) 28.5 (in range)
a

Antinuclear antibody frequently present in individuals with SLE; may suggest more serious SLE.

b

identifies autoantibodies characteristic of autoimmune disorders; most individuals with SLE have positive ANA.

c

Lupus anticoagulants (LA) are antiphospholipid antibodies that specifically target phospholipids and associated proteins and can interfere with blood clotting.

d

Cardiolipin is another antiphospholipid antibody. The presence of LA and cardiolipin do not indicate a diagnosis of SLE; however, these tests can indicate potential risk of complications from antiphospholipid antibodies in SLE patients, such as miscarriage, blood clot, or stroke.

e

Partial thromboplastin time (PTT) measures time it takes for blood to clot and can identify if blood contains anticoagulant antibodies.

f

Blood marker for inflammation.

g

Low levels of complement C3 and C4 reflect inflammation.

– indicates test not performed.